73 completed, 7 recruiting, 7 unknown, 2 active not recruiting. 29 Phase 1, 22 Phase 4, 19 Phase 3, 9 Phase 2, 1 Not applicable.
Follow JW Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers JW0061 SAD, JW0061 MAD, Placebo - Healthy | Phase 1 | Recruiting | JW Pharmaceutical | 104 | 2026-04-13 | 2026-04-23 |
| PROGAIN Trial in Gastric Cancer Surgery Protein-enriched peripheral parenteral nutrition (Winuf A+ injection), Standard peripheral parenteral nutrition (Winuf injection) - Stomach (Gastric) Cancer | Phase 3 | Recruiting | Soonchunhyang University Hospital | 110 | 2026-02-13 | 2026-05-19 |
| to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia KLH-2109+ Leurprorelin acetate Placebo, KLH-2109 Placebo + Leurprorelin acetate - Menorrhagia, Uterine Fibroids | Phase 3 | Recruiting | JW Pharmaceutical | 254 | 2026-02-03 | 2026-05-01 |
| To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers Epaminurad 9 mg (JW Pharmaceutical), Epaminurad 9 mg (Shanghai STA Pharmaceutical) - Healthy | Phase 1 | Completed | JW Pharmaceutical | 34 | 2026-02-02 | 2026-08-13 |
| Glycemic Variability of Combination Therapies in T2DM Empagliflozin/Metformin, Anagliptin, Metformin - Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Recruiting | JW Pharmaceutical | 178 | 2025-10-29 | 2026-03-02 |
| To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects 14C Epaminurad Oral Solution - Healthy Male Adults | Phase 1 | Completed | JW Pharmaceutical | 8 | 2025-08-22 | 2026-04-23 |
| Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study Dyslipidemias | Recruiting | JW Pharmaceutical | 10000 | 2025-06-25 | 2026-04-13 | |
| Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia JW0108 + C2407, JW0108 + C2407 placebo - Dyslipidemia | Phase 3 | Completed | JW Pharmaceutical | 145 | 2025-04-03 | 2025-09-03 |
| PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers Epaminurad 9 mg, C2406 - Healthy Volunteers | Phase 1 | Completed | JW Pharmaceutical | 18 | 2025-03-24 | 2026-04-20 |
| To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 Treatment A_Period 1, Treatment B_Period 2, Treatment A_Period 3 - Healthy | Phase 1 | Completed | JW Pharmaceutical | 60 | 2025-01-17 | 2025-09-09 |
| To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers JW2286, Placebo of JW2286 - Healthy | Phase 1 | Recruiting | JW Pharmaceutical | 72 | 2025-01-06 | 2025-01-13 |
| Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia JW0104+C2402, JW0104+C2403, C2402 - Hypertension, Dyslipidemia | Phase 3 | Recruiting | JW Pharmaceutical | 162 | 2024-12-02 | 2025-09-09 |
| To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107 Treatment A: JW0106 1 tablet + C2101 1 tablet, Treatment B: JW0107 1 tablet - Healthy | Phase 1 | Completed | JW Pharmaceutical | 47 | 2024-09-02 | 2025-02-10 |
| PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers Epaminurad, Naproxen, Epaminurad, Epaminurad placebo - Healthy | Phase 1 | Completed | JW Pharmaceutical | 57 | 2024-06-03 | 2026-04-16 |
| To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers Reference Drug or Test Drug - Healthy | Phase 1 | Completed | JW Pharmaceutical | 56 | 2023-11-03 | 2024-04-11 |
| To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3), Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3), Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3) - Healthy | Phase 1 | Completed | JW Pharmaceutical | 48 | 2023-09-10 | 2024-04-22 |
| Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides Pitavastatin 4mg, Ezetimibe 10 mg, Placebo (for Pitavastatin/Ezetimibe) - Hypercholesterolemia | Phase 4 | Active not recruiting | JW Pharmaceutical | 88 | 2023-08-21 | 2026-03-02 |
| To Evaluate the Safety and PK Characteristics in Healthy Volunteers Reference Drug or Test Drug - Healthy | Phase 1 | Completed | JW Pharmaceutical | 46 | 2023-04-28 | 2024-04-09 |
| A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg - Gout | Phase 3 | Completed | JW Pharmaceutical | 612 | 2023-03-21 | 2026-05-04 |
| To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers Test Drug(JW0302) or Reference Drug(C2206) - Healthy | Phase 1 | Completed | JW Pharmaceutical | 44 | 2023-03-10 | 2024-03-20 |
Showing 20 of 91. Sign in to see all of them.
Diabetes Mellitus, Type 2 (10) · Hypercholesterolemia (8) · Dyslipidemias (6) · Hypertension (6) · Gout (4) · Hyperlipidemias (4) · Prostatic Hyperplasia (4) · Metabolic Syndrome (3) · Stomach Neoplasms (3) · Anemia (2) · Anemia, Iron-Deficiency (2) · Arthritis, Rheumatoid (2) · Diabetes Mellitus (2) · Erectile Dysfunction (2) · Hyperuricemia (2)
pitavastatin (17) · URC102 (6) · Valsartan (5) · silodosin (5) · Drug Evaluation (4) · anagliptin (4) · Atorvastatin (3) · mitiglinide (3) · Antirheumatic Agents (2) · Ezetimibe (2) · Metformin (2) · Sitagliptin Phosphate (2) · Sodium (2) · ferric carboxymaltose (2) · tocilizumab (2)
South Korea (83) · United States (5) · United Kingdom (3) · Germany (2) · Australia (1) · Canada (1) · Czechia (1) · Japan (1) · Poland (1) · Spain (1)
Kyun Seop Bae, MD (2) · Kyung-sang Yu, MD (2) · SeungHwan Lee, PI (2) · Wooseong Hur, MD, PhD (2) · Chang Beom Lee (1) · Chang Woo Kim, MD, PhD (1) · Chang-Ki Min, MD (1) · Cheol-Young Park (1) · Chuhl Joo Lyu, Prof (1) · Chul-Hee Park (1) · D.G. Moon, Prof (1) · D.Y. Yang, Prof (1) · Dae Yul Yang, PhD (1) · Duk-Hyun Kang, M.D. (1)
PMID 31056705, PMID 32508063, PMID 10029607, PMID 10924610, PMID 11910485, PMID 17330243, PMID 1990875, PMID 22410289, PMID 2354408, PMID 24249434, PMID 25378974, PMID 26411328, PMID 29078817, PMID 29739356, PMID 31930513, PMID 32396615, PMID 33261312, PMID 3492188, PMID 36005278, PMID 36241463, PMID 37309696, PMID 38308655, PMID 40420308, PMID 42500128, PMID 42566454, PMID 6125797, PMID 6234037